FEATURED COMPANIES
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
Global Oncology Molecular Diagnostics Market to Reach $3.6 Billion by 2027
Amid the COVID-19 crisis, the global market for Oncology Molecular Diagnostics estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$3.6 Billion by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027. Breast Cancer, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$900.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $490.5 Million, While China is Forecast to Grow at 14.9% CAGR
The Oncology Molecular Diagnostics market in the U.S. is estimated at US$490.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$669.6 Million by the year 2027 trailing a CAGR of 14.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.
Prostate Cancer Segment to Record 12.5% CAGR
In the global Prostate Cancer segment, USA, Canada, Japan, China and Europe will drive the 11.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$233.6 Million in the year 2020 will reach a projected size of US$506.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$533.5 Million by the year 2027, while Latin America will expand at a 14% CAGR through the analysis period.
Select Competitors (Total 44 Featured):
Amid the COVID-19 crisis, the global market for Oncology Molecular Diagnostics estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$3.6 Billion by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027. Breast Cancer, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$900.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $490.5 Million, While China is Forecast to Grow at 14.9% CAGR
The Oncology Molecular Diagnostics market in the U.S. is estimated at US$490.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$669.6 Million by the year 2027 trailing a CAGR of 14.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.
Prostate Cancer Segment to Record 12.5% CAGR
In the global Prostate Cancer segment, USA, Canada, Japan, China and Europe will drive the 11.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$233.6 Million in the year 2020 will reach a projected size of US$506.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$533.5 Million by the year 2027, while Latin America will expand at a 14% CAGR through the analysis period.
Select Competitors (Total 44 Featured):
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
- Leica Biosystems Inc.
- Qiagen NV
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers
- Sysmex Corporation
Frequently Asked Questions about the Global Market for Oncology Molecular Diagnostics
What is the estimated value of the Global Market for Oncology Molecular Diagnostics?
What is the growth rate of the Global Market for Oncology Molecular Diagnostics?
What is the forecasted size of the Global Market for Oncology Molecular Diagnostics?
Who are the key companies in the Global Market for Oncology Molecular Diagnostics?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE
1. MARKET OVERVIEW
III. MARKET ANALYSIS
IV. COMPETITION
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
- Leica Biosystems Inc.
- Qiagen NV
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers
- Sysmex Corporation
Note: Product cover images may vary from those shown
